Zimmer Biomet Holdings, Inc. ZBH

NYSE · Healthcare · Medical - Devices

$101.10

Close on Fri, 20 Nov 2026 · market value $19.1B

What the price is betting on

Below its record

At $101, the price assumes revenue shrinks about 8.4% a year for five years, from $8.6B to about $5.9B by FY2030. That is less than what analysts expect for the next two years and less than the company's own last three years.

The price assumes−8.4%
Analysts, next two years3.4%
Last 3 years5.5%

Revenue growth a year. The price figure comes from a reverse DCF at a 7.2% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than ZBH? Check up to 5 of your stocks at once, free, no account.

0$2.5B$5B$7.5B$10B$8.6B'22'23'24'25Sep '26'26'27'28'29'30What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$183

Base

$206

Bull

$232

Today $101

  • Bear $183. Cash flow grows 2% a year for the next 5 years, slower than expected, then slows to long-run growth.
  • Base $206. Cash flow grows 4% a year for the next 5 years, as analysts expect, then slows to long-run growth.
  • Bull $232. Cash flow grows 6% a year for the next 5 years, faster than expected, then slows to long-run growth.

Stories set by rules from the company’s record.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2026$8.4B$8.6B, on the path
  3. FY2027$7.7B$8.9B, on the path
  4. FY2028$7B$9.2B, on the path
  5. FY2029$6.5B$9.6B, on the path
  6. FY2030$5.9B$10B, on the path

Each year's revenue at −8.4% growth from $8.6B in the 12 months to September 2026.

At a glance

Healthcare · Medical - Devices · listed on NYSE

Revenue, FY2025
$8.2B
Growth, 3 years a year
5.5%
Cash margin
18%
Net debt
$6.9B
Shares, 3-year change
−5.5%
Dividend yield
1%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.